Ibruxen-140mg-Ibrutinib - Imbruvica

Ibruxen-140mg-Ibrutinib (SPC)| Summary of Products’ characteristics

Description

Ibruxen-140mg-Ibrutinib is a medication that can effectively treat many types of cancer, such as mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom’s macroglobulinemia , marginal zone lymphoma, and chronic graft vs host disease.

It works by blocking abnormal proteins that signal cancer cells to multiply, thus preventing the spread of cancer cells. Ibruxen-140mg-Ibrutinib belongs to the kinase inhibitor class, which specifically targets abnormal proteins that signal cancer cells to multiply.

This medication is commonly used to treat individuals with MCL, CLL, SLL, WM, MZL, and cGVHD, which can occur after hematopoietic stem-cell transplants and may last for a long time.Ibruxen-140mg is a highly valuable treatment option for various types of cancer and can significantly improve overall health.

Indication

Ibruxen-140mg-Ibrutinib is a type of targeted therapy drug called a kinase inhibitor. It works by blocking the activity of a protein called Bruton’s tyrosine kinase (BTK). BTK is a protein that plays a role in the growth and survival of cancer cells. By blocking BTK, ibrutinib can help to stop the growth and spread of cancer.

Chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL)

Ibruxen-140mg is indicated for the treatment of adult patients with CLL/SLL:

Who have received at least one prior therapy
With 17p deletion
With high-risk cytogenetics

Mantle cell lymphoma (MCL)

Ibruxen-140mg is indicated for the treatment of adult patients with MCL:

Who have received at least one prior therapy
With high-risk features

Waldenström’s macroglobulinemia (WM)

Ibrutinib is indicated for the treatment of adult patients with WM:

Who have received at least one prior therapy
With high-risk features

cGVHD

Ibrutinib is indicated for the treatment of adult patients with cGVHD after failure of one or more lines of systemic therapy.

Other Potential Indications

Ibruxen-140mg is currently being investigated for the treatment of other types of blood cancers and solid tumors. For example, ibrutinib is being studied in clinical trials for the treatment of acute myeloid leukemia (AML), multiple myeloma, and non-Hodgkin lymphoma.

Ibruxen-140mg Mechanism of Action

Ibruxen-140mg-Ibrutinib specifically blocks the activity of a kinase called Bruton’s tyrosine kinase (BTK). BTK is a protein that plays a role in the B-cell receptor signaling pathway. The B-cell receptor is a protein that is found on the surface of B cells, a type of white blood cell. When the B-cell receptor is activated, it sends signals to the inside of the cell that tell the cell to grow and divide.

BTK is a key protein in the B-cell receptor signaling pathway. By blocking BTK, ibrutinib can stop the B-cell receptor from sending signals to the inside of the cell. This prevents the B cell from growing and dividing, which can lead to cell death.

Ibrutinib is also thought to work by other mechanisms, such as:

Inhibiting the migration of cancer cells to other parts of the body
Promoting the death of cancer cells
Enhancing the activity of the immune system

Dosage and Administration of Ibrutinib

Ibruxen-140mg-Ibrutinib is taken orally once a day, with or without food. The dose of ibrutinib is based on the type of cancer being treated and the patient’s weight.

CLL/SLL and MCL

To treat CLL/SLL or MCL Patients, the starting dose of ibrutinib is 420 milligrams (mg) once a day.

For patients with WM, the starting dose of ibrutinib is 560 mg once a day.

cGVHD

To treat with cGVHD, the starting dose of ibrutinib is 420 mg once a day.

Dose Adjustments

The dose of ibrutinib may be adjusted based on the patient’s response to treatment and side effects. For example, the dose may be reduced if the patient experiences severe side effects.

Ibruxen-140mg-Ibrutinib Side Effects

This list of symptoms includes diarrhea, nausea, constipation, vomiting, stomach pain, heartburn, decreased appetite, excessive tiredness, muscle spasms, swelling, rash, itching, mouth and throat sores, anxiety, difficulty sleeping, cough, runny nose, blurred vision, dry eyes, and pink eye.

Cost of Ibrutinib

Cost of Ibrutinib in USA $17,929 for a supply of 90 capsules, depending on the pharmacy you visit.

Imbruvica has a list price of 55,954.50 pounds ($78,000) a year, although it is being offered at an undisclosed discount to the National Health Service by European supplier Janssen, a unit of Johnson & Johnson.

Ibrutinib cost in UAE, Qatar, Kuwait and other middle east country is yearly near $7,000

Ibruxen 140mg is made in Bangladesh which is cheaper than any other variant in the world. We deliver ibruxen140mg all over the world. Ibrutix140mg is the another similer medication like ibruxen140mg manufactured by one of the Bangladeshi renowned pharmaceutical BEACON.

Ibrutinib FDA approval

Ibrutinib was first approved by the FDA on November 13, 2013, for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in patients who have received at least one prior therapy.

Zanubritinib vs Ibrutinib

Feature	Zanubrutinib	Ibrutinib
Approval date	May 3, 2021	August 23, 2013
Indication	Relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)	Relapsed or refractory CLL/SLL, mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia (WM), and chronic graft-versus-host disease (cGVHD)
Dosage	160 mg once daily	420 mg once daily
Mechanism of action	Inhibits Bruton’s tyrosine kinase (BTK)	Inhibits BTK
Efficacy	In a phase 3 trial, zanubrutinib was shown to be superior to ibrutinib in terms of overall survival (OS) and progression-free survival (PFS).	Ibrutinib has also been shown to be effective in treating CLL/SLL, MCL, WM, and cGVHD.
Safety	Zanubrutinib is generally well-tolerated, but the most common side effects include diarrhea, fatigue, bruising and bleeding, and muscle pain.	Ibrutinib is also generally well-tolerated, but the most common side effects include diarrhea, fatigue, bruising and bleeding, muscle pain, nausea and vomiting, rash, headache, fever, cough, and shortness of breath.

Acalubritinib vs Ibrutinib

Feature	Acalabrutinib	Ibrutinib
Approval date	October 13, 2017	November 13, 2013
Indication	Relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)	Relapsed or refractory CLL/SLL, mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia (WM), and chronic graft-versus-host disease (cGVHD)
Dosage	100 mg twice daily	420 mg once daily
Mechanism of action	Inhibits Bruton’s tyrosine kinase (BTK)	Inhibits BTK
Efficacy	In a phase 3 trial, acalabrutinib was shown to be non-inferior to ibrutinib in terms of progression-free survival (PFS). However, acalabrutinib was associated with a lower rate of atrial fibrillation and bleeding.	Ibrutinib has also been shown to be effective in treating CLL/SLL, MCL, WM, and cGVHD.
Safety	Acalabrutinib is generally well-tolerated, but the most common side effects include headache, diarrhea, cough, and muscle pain.	Ibrutinib is also generally well-tolerated, but the most common side effects include diarrhea, fatigue, bruising and bleeding, muscle pain, nausea and vomiting, rash, headache, fever, cough, and shortness of breath.

Ibrutinib Brand Name

The brand name for ibrutinib is Imbruvica. It is developed by Pharmacyclics, a subsidiary of AbbVie, and was first approved by the FDA in 2013. Imbruvica is a prescription medication used to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in patients who have received at least one prior therapy. It is also used to treat mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia (WM), and chronic graft-versus-host disease (cGVHD).

Searching for other blood cancer or leukemia medicine?

Give a look at them Ventoxen-100mg, Avalet-20mg, Ponaxen-15mg, Ponatinix-15mg, Ibrutix-140mg Ibrucent-140mg, Alecinix-150mg.

For other anti-cancer medicine please visit our product page.

How to buy Ibrutinib?

If you are looking for buying Ibrutinib (Ibruxen-140mg), you are in the right place. To buy Ibrutinib contact with us through WhatsApp (+8801304498958), WeChat, Facebook, and Instagram.

FAQs about Ibrutinib

Can Ibrutinib cause eyes problem?

Yes, ibrutinib can cause eye problems. The most common eye problems associated with ibrutinib are: Dry eyes Red eyes Conjunctivitis (pink eye) Vision changes, such as blurred vision or decreased visual acuity

What is Ibrutinib?

Ibrutinib is a type of targeted therapy drug called a kinase inhibitor. Kinase inhibitors work by blocking the activity of proteins called kinases. Kinases are involved in many cellular processes, including cell growth and proliferation. By blocking kinases, ibrutinib can help to stop the growth and spread of cancer. Ibrutinib specifically blocks the activity of a kinase called Bruton's tyrosine kinase (BTK). BTK is a protein that plays a role in the B-cell receptor signaling pathway. The B-cell receptor is a protein that is found on the surface of B cells, a type of white blood cell. When the B-cell receptor is activated, it sends signals to the inside of the cell that tell the cell to grow and divide.